Full text is available at the source.
Abstract
Healthcare costs were compared for patients treated with metabolic and bariatric surgery or GLP-1 receptor agonists across different insurance payors.
- Metabolic and bariatric surgery may offer different cost implications compared to GLP-1 receptor agonists.
- Variability in reimbursement rates across insurance payors could affect overall healthcare costs for these treatments.
- Understanding these cost differences is important for optimizing treatment decisions in metabolic health.
Simplified